EG236663 Activators
H2al1j, a member of the H2A histone family, assumes a critical role in cellular processes through its predicted DNA binding activity and involvement in heterochromatin assembly. Positioned within the nuclear membrane and nucleoplasm, H2al1j orchestrates chromatin dynamics, impacting gene expression and contributing to the intricate regulation of cellular functions. Activation of H2al1j involves a network of chemicals that modulate epigenetic modifications and chromatin structure. HDAC inhibitors such as Trichostatin A, Valproic Acid, Sodium Butyrate, Entinostat, and Panobinostat foster histone acetylation, indirectly enhancing H2al1j function in DNA binding and heterochromatin assembly. Inhibitors like GSK343, UNC1999, and EPZ-6438 target EZH2, modulating histone methylation and linking H2al1j activation to the intricate regulation of chromatin dynamics. DNA demethylating agents such as 5-Aza-2'-deoxycytidine, RG108, and Decitabine influence gene transcription by indirectly upregulating H2al1j function in DNA binding and heterochromatin assembly.
The general mechanisms of H2al1j activation highlight its sensitivity to epigenetic modifications, emphasizing the role of chromatin dynamics in regulating its DNA binding activity and heterochromatin assembly functions. The diverse network of chemicals influencing H2al1j activation provides insights into the complex interplay between epigenetic regulators and this histone variant, contributing to the understanding of its significance in shaping the epigenomic landscape. H2al1j's involvement in heterochromatin assembly positions it as a key player in maintaining genomic integrity and orchestrating gene expression programs critical for cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a HDAC inhibitor, activates H2al1j by promoting histone acetylation. This leads to altered chromatin dynamics, indirectly enhancing H2al1j function in DNA binding and heterochromatin assembly within the nucleus, emphasizing the link between histone modifications and H2al1j activation. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid, an HDAC inhibitor, activates H2al1j by fostering histone acetylation. This epigenetic modification alters chromatin structure, indirectly enhancing H2al1j function in DNA binding and heterochromatin assembly within the nucleus, highlighting the connection between valproic acid and the modulation of H2al1j activity. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2'-deoxycytidine activates H2al1j through DNA demethylation, influencing gene transcription. The demethylating effect indirectly upregulates H2al1j function in DNA binding and heterochromatin assembly within the nucleus, revealing the impact of DNA methylation dynamics on H2al1j activation. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
GSK343, an EZH2 inhibitor, activates H2al1j by modulating histone methylation. Inhibition of EZH2 alters chromatin dynamics, indirectly enhancing H2al1j function in DNA binding and heterochromatin assembly within the nucleus. The intricate connection between GSK343-mediated histone modifications and H2al1j activation is highlighted. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium Butyrate, an HDAC inhibitor, activates H2al1j by fostering histone acetylation. Altered chromatin structure indirectly enhances H2al1j function in DNA binding and heterochromatin assembly within the nucleus, showcasing the impact of sodium butyrate on epigenetic modifications and the modulation of H2al1j activity. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999, a G9a inhibitor, activates H2al1j by modulating histone methylation. Inhibition of G9a alters chromatin dynamics, indirectly enhancing H2al1j function in DNA binding and heterochromatin assembly within the nucleus. The intricate connection between UNC1999-mediated histone modifications and H2al1j activation is highlighted. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275, an HDAC inhibitor, activates H2al1j by promoting histone acetylation. Altered chromatin structure indirectly enhances H2al1j function in DNA binding and heterochromatin assembly within the nucleus, emphasizing the link between histone modifications and H2al1j activation. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a BET protein inhibitor, activates H2al1j by disrupting chromatin interactions. The consequent release of BET proteins from chromatin indirectly upregulates H2al1j function in DNA binding and heterochromatin assembly within the nucleus, revealing the impact of chromatin dynamics on H2al1j activation. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108, a DNA methyltransferase inhibitor, activates H2al1j through DNA demethylation, influencing gene transcription. The demethylating effect indirectly upregulates H2al1j function in DNA binding and heterochromatin assembly within the nucleus, highlighting the impact of DNA methylation dynamics on H2al1j activation. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat, an HDAC inhibitor, activates H2al1j by fostering histone acetylation. Altered chromatin structure indirectly enhances H2al1j function in DNA binding and heterochromatin assembly within the nucleus, showcasing the impact of panobinostat on epigenetic modifications and the modulation of H2al1j activity. | ||||||